Latest News and Press Releases

Company announcement – No. 76 / 2021 Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel...

Company announcement – No. 75 / 2021 Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital Agreement includes an upfront payment of $100 million in exchange...

Company announcement – No. 74 / 2021 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, DK and Boston, MA, U.S. December 10, 2021 – Zealand...

Company announcement – No. 73 / 2021 Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021 Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S...

Company announcement – No. 72 / 2021 Total number of shares and voting rights in Zealand Pharma at November 30, 2021 Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S (“Zealand”)...

Company announcement – No. 71 / 2021 Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021 Copenhagen, DK and Boston, MA, November 29, 2021 – Zealand Pharma A/S (“Zealand”)...

Company announcement – No. 70 / 2021 Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide Dapiglutide was assessed to be safe and...

Company announcement – No. 69/ 2021 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, DK and Boston, MA, U.S. November 19, 2021 – Zealand...

Company announcement – No. 68 / 2021 Zealand Pharma to Participate in Jefferies London Healthcare Conference Copenhagen, DK and Boston, MA, U.S. November 12, 2021 – Zealand Pharma A/S (Nasdaq:...

Company announcement – No. 67/ 2021 Interim report for 9M 2021 Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and...